SG10201403986UA - High Density Compositions Containing Posaconazole And Formulations Comprising The Same - Google Patents

High Density Compositions Containing Posaconazole And Formulations Comprising The Same

Info

Publication number
SG10201403986UA
SG10201403986UA SG10201403986UA SG10201403986UA SG10201403986UA SG 10201403986U A SG10201403986U A SG 10201403986UA SG 10201403986U A SG10201403986U A SG 10201403986UA SG 10201403986U A SG10201403986U A SG 10201403986UA SG 10201403986U A SG10201403986U A SG 10201403986UA
Authority
SG
Singapore
Prior art keywords
formulations
same
high density
compositions containing
density compositions
Prior art date
Application number
SG10201403986UA
Inventor
Larry Yun Fang
David Harris
Gopal Krishna
Allen E Moton Jr
Russell C Prestipino
Marc Steinman
Jiansheng Wan
Hetty Anne Waskin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201403986U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201403986UA publication Critical patent/SG10201403986UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201403986UA 2008-04-15 2009-04-15 High Density Compositions Containing Posaconazole And Formulations Comprising The Same SG10201403986UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US16648709P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
SG10201403986UA true SG10201403986UA (en) 2014-10-30

Family

ID=41199703

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201403986UA SG10201403986UA (en) 2008-04-15 2009-04-15 High Density Compositions Containing Posaconazole And Formulations Comprising The Same

Country Status (19)

Country Link
US (2) US20110123627A1 (en)
EP (1) EP2285351A2 (en)
JP (3) JP2011516612A (en)
KR (1) KR20110004852A (en)
CN (2) CN102065842A (en)
AR (1) AR072858A1 (en)
AU (1) AU2009236289B2 (en)
BR (1) BRPI0910627A2 (en)
CA (1) CA2720849A1 (en)
CL (1) CL2009000902A1 (en)
CO (1) CO6311066A2 (en)
MX (1) MX2010011295A (en)
NZ (1) NZ588460A (en)
PE (1) PE20091778A1 (en)
PH (1) PH12015500492A1 (en)
SG (1) SG10201403986UA (en)
TW (1) TWI388324B (en)
WO (1) WO2009129300A2 (en)
ZA (1) ZA201007370B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
JP6007322B2 (en) * 2013-06-03 2016-10-12 信越化学工業株式会社 Composition for hot melt extrusion and method for producing hot melt extruded product using the same
EP2837391B1 (en) * 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (en) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 Posaconazole solid dispersion and preparation method thereof
CN104546667A (en) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 Solid dispersion containing posaconazole and preparation method thereof
CN104721827A (en) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 Insoluble antifungal medicament solid dispersion and preparation method thereof
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CN104971045A (en) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 Posaconazole medicine composition, preparation method and medicine preparation thereof
ES2759801T3 (en) * 2015-08-08 2020-05-12 Tiefenbacher Alfred E Gmbh & Co Kg Gastro-resistant formulation containing posaconazole
EP3210599A1 (en) 2016-02-26 2017-08-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (en) * 2016-09-22 2017-01-04 山东大学 The solid dispersion of a kind of antifungal drug posaconazole and preparation method and application
TR201620462A2 (en) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND PRODUCTION METHOD
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
EP4196096A1 (en) 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (en) * 2020-12-18 2021-04-23 卓和药业集团有限公司 Method for analyzing dissolution rate of posaconazole enteric-coated tablets
EP4181883A1 (en) 2021-11-25 2023-05-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN114184721A (en) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 Method for detecting residual posaconazole solvent

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
KR19990044257A (en) * 1996-05-20 1999-06-25 디르크 반테 Antifungal composition with improved bioavailability
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
GT200100039A (en) * 2000-03-16 2001-12-31 Pfizer INHIBITOR OF THE GLUCOGENO FOSFORILASA.
PL212985B1 (en) * 2001-04-03 2012-12-31 Schering Corp Antifungal composition with enhanced bioavailability
JPWO2003077827A1 (en) * 2002-03-19 2005-07-14 日本新薬株式会社 Method for producing pharmaceutical solid dispersion
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20060062848A1 (en) * 2004-09-17 2006-03-23 Nektar Therapeutics Uk Limited Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
JP2009514884A (en) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
MX2008015275A (en) * 2006-05-30 2009-02-06 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations.
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas

Also Published As

Publication number Publication date
AR072858A1 (en) 2010-09-29
BRPI0910627A2 (en) 2015-09-22
AU2009236289A1 (en) 2009-10-22
CO6311066A2 (en) 2011-08-22
JP2016074698A (en) 2016-05-12
CL2009000902A1 (en) 2010-07-23
ZA201007370B (en) 2011-06-29
TWI388324B (en) 2013-03-11
KR20110004852A (en) 2011-01-14
US20150150990A1 (en) 2015-06-04
US20110123627A1 (en) 2011-05-26
MX2010011295A (en) 2010-11-12
JP2014139230A (en) 2014-07-31
JP2011516612A (en) 2011-05-26
CN102065842A (en) 2011-05-18
WO2009129300A2 (en) 2009-10-22
CN104983701A (en) 2015-10-21
AU2009236289B2 (en) 2014-08-21
WO2009129300A3 (en) 2010-02-11
TW200946121A (en) 2009-11-16
NZ588460A (en) 2012-07-27
PE20091778A1 (en) 2009-11-13
CA2720849A1 (en) 2009-10-22
EP2285351A2 (en) 2011-02-23
PH12015500492A1 (en) 2017-04-10

Similar Documents

Publication Publication Date Title
SG10201403986UA (en) High Density Compositions Containing Posaconazole And Formulations Comprising The Same
HK1219733A1 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
IL242883B (en) Arylamino- and heteroarylamino-substituted dioxoazolines and pharmaceutical compositions comprising them
IL213365A (en) Imidazopyrazine and pharmaceutical compositions comprising the same
EP2200573A4 (en) Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL193297A0 (en) Imidazole-based compounds, compositions comprising them and methods of their use
ZA201008887B (en) Oral compositions and uses thereof
ZA200908806B (en) Antifrezze concerntrate and coolant compositions and preparation thereof
ZA201007920B (en) Oral compositions and uses thereof
EP2142216A4 (en) Particle formulations and uses thereof
IL210226A (en) Azole compounds and pharmaceutical compositions comprising the same
EP2330911A4 (en) Natural preservative alternatives and compositions containing same
IL211204A0 (en) Mucoadherents compositions and their use
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
GB0721291D0 (en) Methods and compositions
HUE047692T2 (en) Pharmaceutical compositions and methods for stabilizing the same
GB0719526D0 (en) Compositions and methods
GB0702871D0 (en) Improved compositions and combinations 1
IL212102A0 (en) Compositions comprising allogeneic th1 memory cells and uses thereof
IL193921A0 (en) Maduramicin compositions and methods
PL2164337T3 (en) Stable and consumable compositions
GB2461611B (en) Composition and use thereof
ZA201008384B (en) Lasalocid compositions and methods
GB2446641B (en) Improved compositions and combinations 2